{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:21:58Z","timestamp":1787455318637,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jtct.2026.07.028","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:34:16Z","timestamp":1785195256000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor-Based Cellular Therapies for Autoimmune Diseases: Immune Reset, Clinical Evidence, and Translational Boundaries"],"prefix":"10.1016","author":[{"given":"Miao","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10416","key":"10.1016\/j.jtct.2026.07.028_bib0001","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.07.028_bib0002","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.028_bib0003","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.028_bib0004","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.028_bib0005","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.028_bib0006","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.028_bib0007","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.028_bib0008","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jtct.2026.07.028_bib0009","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.4049\/jimmunol.1301284","article-title":"B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation","volume":"192","author":"Barnett","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2026.07.028_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214898","article-title":"Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B-cell receptor repertoire","author":"Pollastro","year":"201978101339","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtct.2026.07.028_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","author":"Mahevas","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jtct.2026.07.028_bib0012","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43(1)","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.jtct.2026.07.028_bib0013","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125(11)","author":"Mei","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.028_bib0014","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.028_bib0015","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred cells","volume":"202(7)","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.028_bib0016","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"23","key":"10.1016\/j.jtct.2026.07.028_bib0017","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","article-title":"Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis","volume":"188","author":"Qin","year":"2025","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.028_bib0018","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.028_bib0019","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.028_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.028_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.028_bib0022","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","article-title":"Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Wang","year":"2025","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jtct.2026.07.028_bib0023","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.jtct.2026.07.028_bib0024","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N Engl J Med"},{"issue":"10522","key":"10.1016\/j.jtct.2026.07.028_bib0025","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1016\/S0140-6736(25)01671-X","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"406","author":"Gao","year":"2026","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jtct.2026.07.028_bib0026","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2026.07.028_bib0027","unstructured":"ClinicalTrials.gov. Study of single doses of SBT777101 in subjects with rheumatoid arthritis (Regulate-RA) CAR regulatory T-cell study. NCT06201416. Accessed July 11, 2026."},{"issue":"12","key":"10.1016\/j.jtct.2026.07.028_bib0028","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2026.07.028_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.028_bib0030","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"10.1016\/j.jtct.2026.07.028_bib0031","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","article-title":"Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial","volume":"32","author":"Volkov","year":"2024","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.028_bib0032","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/s41591-025-04191-8","article-title":"Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases","volume":"32","author":"Becilli","year":"2026","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.028_bib0033","doi-asserted-by":"crossref","first-page":"keag273","DOI":"10.1093\/rheumatology\/keag273","article-title":"CAR-T as a salvage treatment in polyrefractory RA","volume":"65","author":"Lidar","year":"2026","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.028_bib0034","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJMoa2509820","article-title":"CD19 CAR T-cell therapy for autoimmune hemolytic anemia","volume":"394","author":"Li","year":"2026","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.028_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101039","article-title":"Anti-CD19 CAR T cell therapy for refractory SLE-ITP","volume":"7","author":"Li","year":"2026","journal-title":"Med."},{"issue":"6","key":"10.1016\/j.jtct.2026.07.028_bib0036","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jtct.2026.07.028_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1298815","article-title":"Concurrent remission of lymphoma and Sj\u00f6gren's disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report","volume":"14","author":"Sheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.07.028_bib0038","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25(4)","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.028_bib0039","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2026.07.028_bib0040","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the American Society for Transplantation and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.07.028_bib0041","series-title":"Considerations for the development of chimeric antigen receptor (CAR) T cell products","year":"2024"},{"key":"10.1016\/j.jtct.2026.07.028_bib0042","series-title":"Long term follow-up after administration of human gene therapy products","year":"2020"},{"key":"10.1016\/j.jtct.2026.07.028_bib0043","unstructured":"US Food and Drug Administration. FDA requires boxed warning for T-cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T-cell immunotherapies. April 18, 2024."},{"issue":"9","key":"10.1016\/j.jtct.2026.07.028_bib0044","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jtct.2026.07.028_bib0045","unstructured":"Foundation for the Accreditation of Cellular Therapy; Joint Accreditation Committee ISCT-Europe and EBMT. International Standards for Immune Effector Cells, Third Edition, version 3.1. Effective February 2, 2026."},{"key":"10.1016\/j.jtct.2026.07.028_bib0046","unstructured":"US Food and Drug Administration. FDA eliminates risk evaluation and mitigation strategies (REMS) for autologous chimeric antigen receptor CAR T-cell immunotherapies. June 27, 2025."},{"key":"10.1016\/j.jtct.2026.07.028_bib0047","article-title":"Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2026.07.028_bib0048","article-title":"Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance","volume":"383","author":"Yap","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2026.07.028_bib0049","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/s41591-025-03668-w","article-title":"SPIRIT 2025 statement: updated guideline for protocols of randomized trials","volume":"31(6)","author":"Chan","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.028_bib0050","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-025-03635-5","article-title":"CONSORT 2025 statement: updated guideline for reporting randomized trials","volume":"31(6)","author":"Hopewell","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.07.028_bib0051","unstructured":"ClinicalTrials.gov. Representative autoimmune CAR programs: NCT05869955, NCT05798117, NCT06138132, NCT06733935, NCT07295847, NCT07583030, and NCT07526493. Accessed July 11, 2026."},{"key":"10.1016\/j.jtct.2026.07.028_bib0052","unstructured":"US Food and Drug Administration. Flexible requirements for cell and gene therapies to advance innovation. January 11, 2026."},{"key":"10.1016\/j.jtct.2026.07.028_bib0053","unstructured":"European Society for Blood and Marrow Transplantation. EBMT CAR-T Data Collection Initiative. Accessed July 11, 2026."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726005907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:14:22Z","timestamp":1787454862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726005907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":53,"alternative-id":["S2666636726005907"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.028","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor-Based Cellular Therapies for Autoimmune Diseases: Immune Reset, Clinical Evidence, and Translational Boundaries","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}